Study Reveals Cardiovascular Disease Afflicted People Trigger Off Quit Smoking On A Larger Scale With Chantix/Champix In Comparison To Placebo Takers
Date: 31st March 2009
A study presented at the American College of Cardiology 58th Annual Scientific Session in Orlando, Fla, yields that while only 13.9 percent of people taking placebo were able to quit smoking, a huge 47 percent of smokers showing a history of cardiovascular disease successfully facilitated smoking cessation with chantix / champix and completely abstained from smoking during the last four weeks of their treatment.
The specific Chantix experiment was reportedly funded by the Chantix maker Pfizer Incl. and it was a placebo-controlled, double-blind and multicenter experiment. However, the experiment involved 714 adult patients within the age group 35-75 years and all these participants had smoked around 10 or more cigarettes on a daily basis in the year prior to taking part in the study. All the participants taking part in the study were in the grip of documented as well as stable cardiovascular disease that was not diagnosed more than two months earlier to the experiment and also, sources reveal that they had wished to facilitate quit smoking but had not attempted in the last three months. Some of the diagnoses of cardiovascular disease were chest pain, heart surgery, stroke/ transient ischemic attack, peripheral arterial vascular disease, history of heart attack and a specific type of heart surgery.
According to Dr. Nancy A. Rigotti, the leading researcher of the study who is also Harvard Medical School’s professor of medicine and director of Tobacco Research and Treatment Center at Massachusetts General Hospital, the specific results obtained from the chantix study resemble the findings procured from pivotal varenicline experiments that further reveal that varenicline yields a higher degree of efficacy than placebo among healthy smokers.
Dr. Nancy A. Rigotti also states that the safety report of varenicline observed in this study proves to be considerably similar to the other important studies and the medicine chantix (varenicline) has emerged as effective in helping smokers afflicted with cardiovascular disease to trigger off smoking cessation. However, she adds that the results are specifically cheering as due to their cardiovascular disease history, period of quit smoking and advanced age, the participants were at considerably higher risk of falling prey to death.
Sources altogether reveal that the chantix experiment was initiated in 15 countries.
Source: http://www.businesswire.com/ |
